Alaunos Therapeutics Inc(TCRT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 29 at 4:00 AM ET (Korea 9/29 17:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.95 | Insider Own | 17.06% | Shs Outstand | 2.5M | Perf Week | -19.05% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 2.4M | Perf Month | -38.55% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | - | Inst Own | 3.56% | Short Float | 0.25% | Perf Quarter | -56.96% |
| Income | -0.00B | P/S | - | EPS this Y | - | Inst Trans | -5.33% | Short Ratio | 0.01 | Perf Half Y | -65.77% |
| Sales | 0.00B | P/B | 3.89 | EPS next 5Y | - | ROA | -128.3% | Short Interest | 0.01M | Perf YTD | -68.42% |
| Book/sh | 0.26 | P/C | 24.88 | EPS past 3/5Y | 56.15% 47.89% | ROE | -185.95% | 52W High | -77.78% ($4.59) | Perf Year | -59.12% |
| Cash/sh | 0.04 | P/FCF | - | Sales past 3/5Y | -88.04% - | ROIC | -615.03% | 52W Low | 0% ($1.02) | Perf 3Y | -94.82% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 20.95% | Gross Margin | -700% | Volatility(W/M) | 10.79% 10.47% | Perf 5Y | -99.64% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | -50% | Oper. Margin | -135266.67% | ATR (14) | 0.14 | Perf 10Y | -99.88% |
| Dividend Ex-Date | - | Quick Ratio | 0.77 | EPS Q/Q | 35.2% | Profit Margin | -142700% | RSI (14) | 28.06 | Recom | 2.33 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.77 | Sales Q/Q | - | SMA20 | -28.19% ($1.42) | Beta | -0.92 | Target Price | $3.5 |
| Payout | - | Debt/Eq | 0 | Earnings | - | SMA50 | -40.2% ($1.71) | Rel Volume | 0.19 | Prev Close | $1.09 |
| Employees | 1 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -14.29% - | SMA200 | -59.84% ($2.54) | Avg Volume(3M) | 0.78M | Price | $1.02 |
| IPO | 2005/8/22 | Option/Short | No/Yes | Trades | 381 | Volume | 149,260 | Change | -6.42% |
🧬 Alaunos Therapeutics () is a clinical-stage oncology cell therapy company headquartered in Houston, USA. It develops patient-specific TCR-T (T-cell receptor) cell therapies using its proprietary non-viral Sleeping Beauty gene insertion technology and is a micro-cap biotech stock that has recently been expanding its pipeline into areas such as obesity treatments.
Over the past 1 year, on the lower side
78% below its 1-year high.
Traded less than usual That is 19% of its average volume.
TCRT has weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.6%. The S&P 500 did +77% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 3.6%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VXF Vanguard Extended Market Index ETF <0.01% It ranks #573 of 592 in the industry
Based on market cap of $3M.
JAGX#570 Jaguar Health Inc $3M PER - 
XRTX#571 XORTX Therapeutics Inc $3M PER - 
VRAX#571 Virax Biolabs Group Ltd $3M PER - TCRT#573 Alaunos Therapeutics Inc $3M PER - 
SPRC#574 SciSparc Ltd $3M PER - 
FAQ
What kind of company is TCRT?
TCRT belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of TCRT?
The market cap of TCRT is approximately $3M, ranking 5,790 within its sector.
What is the 52-week high and low for TCRT?
TCRT has recorded a 52-week high of $4.59 and a low of $1.02.
